2-氨基-3-氯苯甲腈 | 53312-77-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-3-氯苯甲腈
• 中文别名: 2-氨基-3-氯苯腈；2-氨基-3-氯氰苯
• 英文名称: 2-amino-3-chlorobenzonitrile
• 英文别名: 2-chloro-6-cyanoaniline
• CAS: 53312-77-9
• 化学式: C₇H₅ClN₂
• 分子量: 152.583
• InChiKey: FAHVRFGAGJMXHW-UHFFFAOYSA-N

物化性质

• 熔点：
  94-96℃
• 沸点：
  266.9±25.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xi
• WGK Germany：
  3
• 海关编码：
  2926909090
• 安全说明：
  S26,S36
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H312,H315,H319,H332
• 储存条件：
  | 室温 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-3-chlorobenzonitrile
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H301: Toxic if swallowed
H312: Harmful in contact with skin
H332: Harmful if inhaled
Causes skin irritation
H315:
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
P280: Wear protective gloves/protective clothing/eye protection/face protection
P301+P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-3-chlorobenzonitrile
CAS number: 53312-77-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C7H5ClN2
Molecular weight: 152.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
UN Number: UN3439 Class: 6.1 Packing group: III
Proper shipping name: NITRILES, TOXIC, SOLID, N.O.S. (2-Amino-3-chlorobenzonitrile)

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氨基-3-氯苯甲腈 在 硼烷四氢呋喃络合物 、 盐酸 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以90%的产率得到2-amino-3-chlorobenzylamine
  参考文献：
  名称：

  2-氨基-3,4-二氢喹唑啉 5-HT3 5-羟色胺受体拮抗剂和相关类似物的 X 射线晶体结构

  摘要：

  某些 2-氨基-3,4-二氢喹唑啉与 5-HT3 血清素受体结合并充当拮抗剂（例如 6-氯），而其他的结合几乎没有亲和力并且缺乏功能活性（例如 8-氯）。本次调查的目的是深入了解为什么会出现这种情况。X 射线晶体学研究表明，所检查类似物中的 NCN 距离几乎相同 (1.31 - 1.34 Å)，表明 NCN 离域的差异并不能解释亲和力/作用的差异。同源性建模疏水相互作用 (HINT) 分析表明，6-氯类似物与受体形成了更多、更有利的相互作用，而 8-氯类似物形成的相互作用较少且不利。

  DOI：

  10.1016/j.molstruc.2019.127276
• 作为产物：
  描述：

  氰化亚铜 、 2,6-二氯苯胺 以 N-甲基吡咯烷酮 为溶剂， 反应 2.5h， 以31%的产率得到2-氨基-3-氯苯甲腈
  参考文献：
  名称：

  酮与邻恶唑啉取代苯胺的新反应

  摘要：

  在干燥的正丁醇中催化量的对甲苯磺酸存在下，各种酮类与邻恶唑啉取代的苯胺反应，以相当高的收率形成4-氨基取代的喹啉或4-喹诺酮。

  DOI：

  10.1016/j.tet.2006.07.057

文献信息

• [EN] COMBINATION PHARMACEUTICAL AGENTS AS RSV INHIBITORS<br/>[FR] AGENTS PHARMACEUTIQUES EN COMBINAISON EN TANT QU'INHIBITEURS DE RSV
  申请人：ENANTA PHARM INC

  公开号：WO2019067864A1

  公开（公告）日：2019-04-04

  The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a Respiratory Syncytial Virus (RSV) infection, wherein treatment comprises administering a compound effective to inhibit the function of the RSV and an additional compound or combinations of compounds having anti-RSV activity.

  本发明涉及用于治疗呼吸道合胞病毒（RSV）感染的药物剂，该药物剂可以单独或连续给予受试者，治疗包括给予一种有效抑制RSV功能的化合物以及具有抗RSV活性的另一种化合物或化合物组合。
• The Cascade Methylation/Cyclization of <i>ortho</i> -Cyanoarylacrylamides with Dicumyl Peroxide
  作者：Tao Yang、Wen-Jin Xia、Bin Zhou、Yangchun Xin、Yuehai Shen、Ya-Min Li

  DOI：10.1002/ejoc.201900918

  日期：2019.9.8

  A radical cascade methylation/cyclization of ortho‐cyanoarylacrylamides was developed by utilizing dicumyl peroxide as a methylation reagent. This transformation provides a simple and straightforward approach to methylated quinoline‐2,4(1H,3H)‐diones, and exhibits a wide substrate scope. Furthermore, this reaction could be readily scaled up.

  通过使用过氧化二枯基作为甲基化试剂，开发了邻-氰基芳基丙烯酰胺的自由基级联甲基化/环化反应。这种转化为甲基化喹啉-2,4（1 H，3 H）-二酮提供了一种简单明了的方法，并具有广泛的底物范围。此外，该反应可以容易地扩大规模。
• Quinazolinones from <i>o</i> -Aminobenzonitriles by One-Pot Sequential Selective Hydration/Condensation/Acceptorless Dehydrogenation Catalyzed by an Iridium Complex
  作者：Wei Zhao、Pengcheng Liu、Feng Li

  DOI：10.1002/cctc.201501385

  日期：2016.4.20

  A new strategy for the direct synthesis of quinazolinones from o‐aminobenzonitriles was proposed and accomplished. In the presence of [Cp*IrCl2]2 (Cp*=pentamethylcyclopentadienyl), a variety of desirable products was obtained easily through the one‐pot sequential selective hydration/condensation/acceptorless dehydrogenation. This protocol is highly attractive because it uses readily available starting

  提出并完成了由邻氨基苯甲腈直接合成喹唑啉酮的新策略。在[Cp * IrCl 2 ] 2（Cp * =五甲基环戊二烯基）的存在下，通过一锅顺序选择性水合/缩合/无受体脱氢可以轻松获得各种所需产物。该协议具有很高的吸引力，因为它使用了容易获得的起始原料，原子效率高，产率高到优，化学药品和能源的消耗最少。值得注意的是，这项研究显示出开发涉及无受体脱氢的过渡金属催化单锅顺序反应的新潜力。
• [EN] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES<br/>[FR] [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES
  申请人：BAYER AG

  公开号：WO2021028382A1

  公开（公告）日：2021-02-18

  The present invention covers [1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds of general formula (I) in which R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of cancer or conditions with dysregulated immune responses or other disorders associated with aberrant AHR signaling, as a sole agent or in combination with other active ingredients.

  本发明涵盖了通式（I）中R1、R2、R3、R4、R5、R6、R7和R8如所定义的[1,2,4]三唑并[1,5-c]喹唑啉-5-胺化合物，以及制备所述化合物的方法，用于制备所述化合物的有用中间体化合物，包含所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗或预防疾病的药物组合物，特别是癌症或与异常AHR信号传导相关的疾病，或与失调免疫反应或其他与异常AHR信号传导相关的疾病有关的情况，作为唯一药剂或与其他活性成分组合使用。
• BENZOPYRAN AND BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
  申请人：Do Steven

  公开号：US20090247567A1

  公开（公告）日：2009-10-01

  Benzopyran and benzoxepin compounds of Formulas I and II, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formulas I and II for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  Benzopyran和benzoxepin的化合物I和II的分子式，包括其立体异构体、几何异构体、互变异构体、溶剂合物、代谢物和药学上可接受的盐，可用于抑制脂质激酶，包括p110 alpha和PI3K的其他同系物，并用于治疗由脂质激酶介导的癌症等疾病。公开了使用分子式I和II的化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病或相关病理条件的方法。